Company intelligence / Profile preview
Arecor Therapeutics
- Ownership
- Public · AREC
- Employees
- ~44
- Development stage
- Other
Overview
Arecor has two proprietary next-generation insulin candidates in clinical development with compelling clinical superiority to current best insulins. AT247 and AT278 are both in Phase I trials. The company also has a partnered product on the market incorporating its technology, generating royalties, and several additional partnered assets at various stages of development[5][6]. Its oral GLP‑1 program aims to improve bioavailability over existing products.
- Therapeutic areas
- Rare DiseasesEndocrinology
- Modalities
- ProteinPeptideSmall molecule
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $47M
- Total revenue
- $2.3M
- Enterprise value
- $42.9M
Beyond the preview
Go deeper on Arecor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arecor Therapeutics.